Vorapaxar: First Global Approval

Vorapaxar [Zontivity ® (US)], an orally active protease-activated receptor-1 (PAR-1) receptor antagonist, has been developed by Merck & Co for the reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) or peripheral arterial disease (PAD). Vorapaxa...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Drugs (New York, N.Y.) N.Y.), 2014-07, Vol.74 (10), p.1153-1163
Hauptverfasser:	Poole, Raewyn M., Elkinson, Shelley
Format:	Artikel
Sprache:	eng
Schlagworte:	Aspirin Biological and medical sciences Blood. Blood coagulation. Reticuloendothelial system Drug Approval Humans Internal Medicine Ischemia Lactones - chemistry Lactones - pharmacology Lactones - therapeutic use Medical sciences Medicine Medicine & Public Health Myocardial Infarction - drug therapy Peripheral Arterial Disease - drug therapy Pharmacology. Drug treatments Pharmacology/Toxicology Pharmacotherapy Platelet Aggregation Inhibitors - chemistry Platelet Aggregation Inhibitors - pharmacology Platelet Aggregation Inhibitors - therapeutic use Prevention Pyridines - chemistry Pyridines - pharmacology Pyridines - therapeutic use R&D Insight Report Receptor, PAR-1 - antagonists & inhibitors Stroke Thrombosis
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Vorapaxar [Zontivity ® (US)], an orally active protease-activated receptor-1 (PAR-1) receptor antagonist, has been developed by Merck & Co for the reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) or peripheral arterial disease (PAD). Vorapaxar has received its first global approval for this indication in the US. This article summarizes the milestones in the development of vorapaxar leading to this first approval for the reduction of thrombotic cardiovascular events in patients with a prior MI or PAD.
ISSN:	0012-6667 1179-1950
DOI:	10.1007/s40265-014-0252-2